In patients with heart failure (HF) and secondary mitral valve regurgitation, transcatheter edge-to-edge repair (TEER) is non-inferior to surgical mitral valve repair or replacement with respect to a composite of death, hospitalization for HF, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial presented at the ESC Congress 2024.

The MATTERHORN study was an investigator-initiated non-inferiority trial conducted in Germany. In total, 210 patients with HF and secondary mitral regurgitation who continued to have symptoms despite receiving guideline-directed medical therapy (mean age 70.5 years, 39.9% women) were randomly assigned to undergo TEER or surgical mitral valve repair or replacement.